Previous Page  12 / 19 Next Page
Information
Show Menu
Previous Page 12 / 19 Next Page
Page Background

Gastro Education 2018

Journal of Clinical Gastroenterology and Hepatology

ISSN: 2575-7733

Page 26

September 06-07, 2018

London, UK

14

th

International Conference on

Gastro Education

P

ancreatic cancer accounts for 3%of all cancers, is the 3rdmost

common cause of cancer death, has a 30month survival of the

tumourwhich is less than1cm indiameter, less than1%of patients

benefit from surgery and 20% of patients who undergo Whipple’s

procedure survive for 5 years. Two radiofrequency devices

were invented by an Imperial College London spin out company,

Emcision Limited (recently acquired by Boston Scientific Inc)

trying to treat inperable pancreatic cancers using an endoscopic

approach. The EndoHPB (Endoscopic Bipolar Radiofrequency

Probe) is a bipolar device delivered endoscopically that has been

shown in three different studies to improve survival following

radiofrequency ablation prior to biliary stent placement. The EUS-

RFA (Endoscopic uitrasound guided radiofrequency ablation)

device is a monoplar radiofrequnecy device which is delivered

using echoendoscope. In a a multi-centre, pilot safety study

in 8 patients 6 had pancreatic cystic neoplasm and two had a

neuroendocrine tumours (NET) in the head of pancreas. EUS-RFA

was successfully completed in all cases. Among the 6 patients

with a cystic neoplasm, post procedure imaging in 3-6 months

showed complete resolution of the cysts in 2 cases, whilst in three

more there was a 48.4% reduction in size. In the NET patients,

there was a change in vascularity and central necrosis after EUS-

RFA. No major complications were observed within 48 h of the

procedure. This preliminary data suggest that the procedure is

straightforward and safe. The response ranged from complete

resolution to a 50% reduction in size.

Biography

Nagy Habib is the Head of Surgery at the Hammersmith Campus of Imperial

College London, UK. He is a Translational Researcher who pioneered the first

clinical trial of the use of plasmid and adenovirus for the treatment of liver

cancer, as well as the use of plasmid gene therapy in hydrodynamic gene

delivery. He is the Principal Investigator of world first clinical trials published

on the use of adult bone marrow-derived stem cells for the treatment of pa-

tients with liver insufficiency and CD34+ cells for patients with stroke. He is

the Inventor and Co-author on the first publication to describe the use of ra-

diofrequency energy in devices for liver surgery (Habib 4X), and interventional

endoscopy (Habib™ EndoHPB and Habib™ EUS-RFA).

nagy.habib@imperial.ac.uk

Endoscopic radiofrequency ablation for biliary and Pancreatic

cancers

Nagy Habib

Imperial College London, UK

Nagy Habib, J Clin Gastroenterol Hepatol 2018, Volume 2

DOI: 10.21767/2575-7733-C2-006